Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia

Annals of Hematology

Volumn 90, Issue 5, 2011, Pages 611-612

  Fodstad, Philip ^a   Dheyauldeen, Sinan ^a   Rinde, Marit ^b   Bachmann Harildstad, Gregor ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRON; THALIDOMIDE; TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ARGON PLASMA COAGULATION; ARTERIOVENOUS MALFORMATION; ARTIFICIAL EMBOLISM; CASE REPORT; DISEASE SEVERITY; DOUBLE BALLOON ENTEROSCOPY; DRUG DOSE REDUCTION; ENDOGLIN GENE; EPISTAXIS; ERYTHROCYTE CONCENTRATE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LAPAROTOMY; LETTER; LIVER ARTERIOVENOUS MALFORMATION; MALE; NORWAY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PULMONARY ARTERIOVENOUS FISTULA; PULSED DYE LASER; RENDU OSLER WEBER DISEASE; SPLICING DEFECT;

ADULT; ANEMIA; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; EPISTAXIS; HEMATINICS; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79956101052     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-010-1063-5     Document Type: Letter

References (6)

1. Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85(9):631-632 (Pubitemid 44283088)
2. Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143-2144
3. Mahoney EJ, Shapshay SM (2006) New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia. Am J Rhinol 20(1):87-90
4. Jameson JJ, Cave DR (2004) Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 114(4):705-709 (Pubitemid 38548784)
5. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M (2009) Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 119 (2):284-288
6. Mitchell A, Adams LA, Macquillan G, Tibballs J, vanden Driesen R, Delriviere L (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14(2):210-213